Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :


---------------------

Frontiers in Medical Sciences Lecture Series 240-
Myeloid-derived suppressor cells are coming to age
...
...
..

Nice to see Dmitry Gabriloich involved here, along with the rest of the NCCN affiliates. Lots of Bavituximab and PS Targeting discussions going on I'd say...and Dmitry is 1 of about 33 Chairpersons here below, many included are NCCN members.

https://public.era.nih.gov/pubroster/Reports?AGENDA_SEQ_NUM_P=301690&DOCTYPE=SEP&DESFORMAT=PDF

-----------------------------------------------------------------

One can dig deeper and truly see that Peregrine Pharmaceuticals inches closer on all levels or one can allow some posts to deter them from realizing the obvious. Dig deeper I say and never allow some to force you to pay a higher, hefty price for a share of PPHM.

Look at all the names.... even Bernard Fox is in there and I know its difficult to see, especially if one is looking into Peregrine harmaceuticals for the very first time. If one can take a walk into my view of yellow stickies posted over the house..... it is 100% clear. Biomarkers to Immunoprofiling will soon erase decades of FDA approvals that many will be scientifically proven to have DECREASED your immune response ability and actually caused much of the trouble. The trouble begins with flipped PS. The trouble is now, that Big Pharma must make room for Peregrine Pharmaceuticals. Move over.... PS Targeting should take front and center stage and all those against Peregrine, are 100% against advancing the treatment of cancer.

-----------------------------------------------------------

IMMUNOPROFILING
Researchers presented preliminary results for a new custom assay designed to provide detailed profiles of immune activity in patient tumors. The Opal 6-plex quantitative immunofluorescence (IF) assay is specifically designed to measure the level and type of lymphocytes, myeloid and dendritic cell subsets found within the tumor microenvironment. This information is important as it can be used to correlate immune response parameters with bavituximab treatment outcome and patient survival.

Presented results demonstrated that the Opal assay could reliably detect, measure and phenotype lymphocytes and monocytes present in tumor tissues from rectal adenocarcinoma, hepatocellular carcinoma and advanced melanoma patients treated with bavituximab combination therapies. Importantly, the findings were able to show changes in key indicators of immune activation, including CD8+, CD4+ and regulatory T-cells, as well as myeloid and dendritic cells, in the tumor microenvironment following bavituximab treatment. The ability of this new assay to accurately measure specific immune responses is expected to provide important additional information to assist in Peregrine's ongoing development efforts for bavituximab. This will be particularly valuable as the company works to better elucidate the connection between the drug candidate's impact on immunomodulation and patient response to treatment.

"We are very pleased with the performance of the Opal assay, particularly its ability to compare the interaction of up to 6 phenotypic and functional markers on a single slide of tissue. The power and prognostic value of such immune activity assessments in the area of cancer was initially established by the Immunoscore [ www.immunoscore.org ], and we believe the Opal assay represents an important evolution of that work," said Bernard A. Fox, Ph.D., Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Cancer Center; a world-renowned translational cancer immunotherapist; a founding member of the Immunoscore steering committee

http://www.ohsu.edu/xd/education/schools/school-of-medicine/academic-programs/graduate-studies/faculty/grad-studies-faculty.cfm?facultyid=104

"I am looking forward to continued collaboration with Peregrine to further optimize and validate this assay to improve our understanding of immune infiltrate in tumors thereby facilitating the rational design and use of bavituximab in combination with novel and standard therapies."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118351795

Maybe Robert H. Schwartz ex-BMS or Howard Jack West -big BMS backer or Gerald Finken ex-BMS current CEO CSM Fargo ND or even non MD's such as Jeanette Bleecker Fargo ND ex-CSM employee that literally sabotaged at least one trial and likely others.... should all be reminded of the oath that MD's take and when working in this field remember it well.

---------------------------------------------

Hippocratic Oath
..
..
At the time of being admitted as a member of the medical profession:

I solemnly pledge to consecrate my life to the service of humanity;
I will give to my teachers the respect and gratitude that is their due;
I will practice my profession with conscience and dignity;
The health of my patient will be my first consideration;
I will respect the secrets that are confided in me, even after the patient has died;
I will maintain by all the means in my power, the honour and the noble traditions of the medical profession;
My colleagues will be my sisters and brothers;
I will not permit considerations of age, disease or disability, creed, ethnic origin, gender, nationality, political affiliation, race, sexual orientation, social standing or any other factor to intervene between my duty and my patient;
I will maintain the utmost respect for human life;
I will not use my medical knowledge to violate human rights and civil liberties, even under threat;
I make these promises solemnly, freely and upon my honour.

https://en.wikipedia.org/wiki/Declaration_of_Geneva
..
..
..
Breaking the Hippocratic Oath

There is not any direct punishment for breaking the Hippocratic oath in modern times. It can be said that malpractice is the same thing and it carries a wide range of punishments from legal action to civil penalties.[23] In the US, several major judicial decisions have made reference back to the classical Hippocratic Oath, either upholding or dismissing its bounds for medical ethics: Roe v Wade, Washington v. Harper, Compassion in Dying v. State of Washington (1996), and Thorburn v. Department of Corrections (1998).[24] In antiquity, the punishment for breaking the Hippocratic oath could range from a penalty to losing the right to practice medicine.[25]

https://en.wikipedia.org/wiki/Hippocratic_Oath